Rhenman & Partners Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-235,210	Closed	-$2.64M	–	94
2022 Q4	$2.64M	Hold	235,210	–	–	0.28%	76
2022 Q3	$2.49M	Hold	235,210	–	–	0.26%	80
2022 Q2	$1.99M	Hold	235,210	–	–	0.23%	79
2022 Q1	$3.2M	Buy	235,210 +49,000	+26%	+$792K	0.32%	76
2021 Q4	$3.62M	Hold	186,210	–	–	0.24%	81
2021 Q3	$5.98M	Hold	186,210	–	–	0.42%	66
2021 Q2	$6.3M	Buy	186,210 +11,210	+6%	+$401K	0.43%	74
2021 Q1	$6.57M	Hold	175,000	–	–	0.46%	61
2020 Q4	$5.81M	Buy	+175,000	New	+$7.09M	0.47%	62

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Rhenman & Partners Asset Management's PHAT Position: Q1 2023 in Review

Rhenman & Partners Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2023, closing a stake of 235,210 shares — an estimated $2.64M sold.

Rhenman & Partners Asset Management first reported a position in PHAT in Q4 2020 and held it in 9 quarters. The position peaked at $6.57M in Q1 2021. 84 funds tracked by Wall St. Rank hold PHAT as of Q1 2023.

Rhenman & Partners Asset Management reported no remaining Phathom Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 235,210 Phathom Pharmaceuticals shares in Q1 2023, an estimated $2.64M.
Rhenman & Partners Asset Management first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 9 quarters.
Rhenman & Partners Asset Management's Phathom Pharmaceuticals position peaked at $6.57M in Q1 2021.
84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.